A
Alto Neuroscience
Biotech & Life Sciences · Los Altos, United States · Founded 2019
Clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform MoreLess
Alto Neuroscience is a cutting-edge startup that operates in the healthcare sector, specifically in the field of psychiatric drug development. The company's primary focus is on creating precision medicines for the brain, a novel approach that is set to revolutionize the psychiatric medication industry. Alto Neuroscience's unique selling proposition is its use of artificial intelligence (AI) to identify brain biomarkers, which are biological measures of mental health conditions.
The company's business model is centered around the development and commercialization of these AI-driven, precision psychiatric drugs. They use a data-driven biomarker platform to match the right patient with the right Alto drug. This approach is based on a decade of clinical neuroscience research and leverages a rich in-human data set, making their solutions highly personalized and potentially more effective.
Alto Neuroscience's primary clients are patients suffering from psychiatric conditions who could benefit from a more personalized approach to their medication. The company operates in the pharmaceutical market, which is a multi-billion dollar industry with significant growth potential.
The company generates revenue by developing and selling these precision psychiatric drugs. As a clinical-stage company, they are likely in the process of conducting clinical trials and seeking regulatory approval for their drugs. Once approved, these drugs can be sold to healthcare providers and patients, providing a steady stream of revenue for the company.
In conclusion, Alto Neuroscience is a promising startup in the healthcare sector that is leveraging AI and precision medicine to redefine psychiatric drug development.
Keywords: Alto Neuroscience, healthcare sector, psychiatric drug development, precision medicine, artificial intelligence, brain biomarkers, data-driven biomarker platform, personalized medication, pharmaceutical market, clinical-stage company.
Company overview
Alto Neuroscience company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Los Altos, United States
- Employees
- 87
- Open positions
- 1
- Dealroom signal
- 84.1
Valuation & funding
Alto Neuroscience funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Mar 2026 | $120M | — | Perceptive Advisors · Venrock · Driehaus Capital Management · Commodore Capital | ↗ |
| PRIVATE PLACEMENT VCOther financing | Oct 2025 | $50M | — | Commodore Capital · Vestal Point Capital · Vivo Capital · Perceptive Advisors | ↗ |
| IPOOther financing | Feb 2024 | $129M | $129M | Undisclosed | ↗ |
| SERIES COther financing | Nov 2023 | $45M | $180M | Eli Lilly · Alpha Wave Ventures · InVivium Capital · Windham Venture Partners | ↗ |
| DEBTDebt | Jan 2023 | $35M | — | K2 HealthVentures | ↗ |
| SERIES BOther financing | Jan 2023 | Alpha Wave Global · Presight Capital | ↗ | ||
| SERIES BOther financing | Oct 2022 | Valor Equity Partners · The Sobrato Organization · Novartis · Gaingels | ↗ | ||
| SERIES BOther financing | Mar 2022 | Bioverge | — | ||
| SERIES AOther financing | Oct 2021 | Tim Kendall · Windham Venture Partners · Apeiron Investment Group · Able Partners | — | ||
| FundingOther financing | Mar 2021 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$109M | — |
| 2025 | $0 | — | −$59M | — |
| 2024 | $0 | — | −$60M | — |
| 2023 | $0 | — | −$35M | — |
| 2022 | $0 | -100% | −$27M | — |
| 2021 | $210K | — | −$8.8M | -4204.8% |
Growth signals
Alto Neuroscience website traffic
Latest recorded traffic for Alto Neuroscience is 7.9K monthly website visits, down 50.6% over the last three months. Alto Neuroscience's team grew 13% over the past year.
Hiring
Open positions at Alto Neuroscience
Current openings linked to this company in Dealroom.
Comparisons
Alto Neuroscience compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Alto Neuroscience's talent
Source: Dealroom Talent Intelligence.
Investors
34 investors on Alto Neuroscience's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Alto Neuroscience has talent and traffic
team presence
In the news
Latest news about Alto Neuroscience
Recent press, funding announcements, and product moves mentioning Alto Neuroscience — open to read from the original sources.
Market sentiment
What the market is saying about Alto Neuroscience
An AI-synthesized read of the highest-engagement posts about Alto Neuroscience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alto Neuroscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.